Neoadjuvant Chemotherapy With Docetaxel, Cisplatin Followed by Maintenance Therapy With the EGFR Inhibitor Erlotinib (Tarceva) in Patients With Stage I, II and III Non-Small Cell Lung Cancer Following Definitive Surgical Resection.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 03 Aug 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 14 Oct 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.